Antidiabetic therapy reduces CV mortality and HF outcomes in high-risk patients

3' education - Nov. 10, 2015 - AHA 2015, Orlando, FL, USA - Prof. Silvio Inzucchi

Video navigation menu

The EMPA-REG CV OUTCOME trial of empagliflozin 0:00
Heart failure outcomes in the EMPA-REG OUTCOME trial 1:46
Does presence of HF at baseline drive the HF outcomes? 2:15
What do these results mean for use of diabetes medication in high-risk individuals? 2:58

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.